THE USE OF CEREBROLYSIN IN MEDICAL REHABILITATION AFTER AN ISCHEMIC STROKE


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

This article analyzes the results of a prospective, randomized, double-blind, placebo-controlled multicenter CARS study («Cerebrolysin And Recovery after Stroke»), which was aimed to the evaluation of the efficacy and safety of use of the drug Cerebrolysin on the background of the rehabilitation measures in the recovery period after a stroke. The study included patients with hemispheric ischemic stroke aged 18 to 80 years. Cerebrolysin or placebo was administered once a day at the dose of 30 ml for 21 days; infusions were started 24 to 72 hours from the stroke onset and lasted for 20 minutes. The results led to the conclusion that the CARS study is the first among the previously conducted clinical trials of neuroprotective agents, in which the primary end point (recovery of motor function) was achieved. These results open up new potentials for the medicamentous support of rehabilitation measures in ischemic stroke patients.

Толық мәтін

Рұқсат жабық

Авторлар туралы

M. Kustova

SRI of Cerebrovascular Pathology and Stroke FSBEI HE RNSMU n.a. N.I. Pirogov of RMH

Moscow

A. Tolmachev

SRI of Cerebrovascular Pathology and Stroke FSBEI HE RNSMU n.a. N.I. Pirogov of RMH

Moscow

N. Shamalov

SRI of Cerebrovascular Pathology and Stroke FSBEI HE RNSMU n.a. N.I. Pirogov of RMH

Email: shamalovn@gmail.com
MD, Prof. at the Department of Fundamental and Clinical Neurology and Neurosurgery, Head of the Department of Treatment and Diagnosis of Stroke Moscow

Әдебиет тізімі

  1. Murray C.J., Lopez A.D. Measuring the global burden of disease. N. Engl. J. Med. 2013;369:448-57.
  2. Avasarala J. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:000-000.
  3. Saver J.L., Smith E.E., Fonarow G.C., Reeves M.J., Zhao X, eOlson D.M., Schwamm L.H.; GWTG Stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41:1431-39.
  4. Zahuranec D.B., Majersik J.J. Percentage of acute stroke patients eligible for endovascular treatment. Neurology. 2012;79(13 suppl 1):S22-S25.
  5. Шамалов Н.А. Проблемы и перспективы реперфузионной терапии при ишемическом инсульте в России. Фарматека. 2015;9(302):14-9.
  6. O'Collins V.E., Macleod M.R., Donnan G.A., Horky L.L., van der Worp B.H., Howells D.W. 1,026 experimental treatments in acute stroke. Ann. Neurol. 2006;59:467-77.
  7. Kaur H., Prakash A., Medhi B. Drug therapy in stroke: from pre- clinical to clinical studies. Pharmacology. 2013;92:324-34.
  8. Xu S.Y, Pan S.Y. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med Sci. Monit Basic Res. 2013;19:37-45.
  9. Tymianski M. Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke. 2013;44:2942-50.
  10. Hossmann K.A. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J. Cereb. Blood Flow Metab. 2012;32:1310-16.
  11. Masliah E., Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today. 2012;48 (suppl A):3-24.
  12. Hartbauer M., Hutter-Paier B., Skofitsch G., Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J. Neural Transm (Vienna). 2001;108:459-73.
  13. Zhang L., Chopp M., Meier D.H., Winter S., Wang L., Szalad A., Lu M., Wei M., Cui Y., Zhang Z.G. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke. 2013; 44:1965-72.
  14. Gutmann B., Hutter-Paier B., Skofitsch G., Windisch M., Gmeinbauer R. In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res. 2002;4:59-65.
  15. Darsalia V., Heldmann U., Lindvall O., Kokaia Z. Stroke-induced neurogenesis in aged brain. Stroke. 2005;36:1790-95.
  16. Скворцова В.И., Стаховская Л.В., Губский Л.В., Шамалов Н.А., Тихонова И.В., Смычков А.С. Рандомизированное двойное слепое плацебо безопасности и эффективности церебролизина для лечения острого ишемического инсульта. Инсульт. Прил. к Журналу неврологии и психиатрии им. С.С. Корсакова 2004; S11:51-5.
  17. Ladurner G., Kalvach P., Moessler H. Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J. Neural Transm (Vienna). 2005;112:415-28.
  18. Ziganshina L.E., Abakumova T., Kuchaeva A. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst. Rev. 2010;4:CD007026.
  19. Lang W., Stadler C.H., Poljakovic Z., Fleet D. Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int. J. Stroke. 2013;8:95-104.
  20. Heiss W.D., Brainin M., Bornstein N.M., Tuomilehto J., Hong Z. Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43:630-36.
  21. Muresanu D.F., Heiss W-D., Hoemberg V., Bajenaru O, Popescu C.D., Vester J.C., Rahlfs V.W., Doppler E., Meier D., Moessler H., Guekht A. Cerebrolysin and Recovery After Stroke (CARS). A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;41:33-43.
  22. Lyle R.C. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int. J. Rehabil. Res. 1981;4:483-92.
  23. Posteraro L., Formis A., Grassi E., Bighi M., Nati P., Proietti Bocchini C., Todeschini E., Bidini C., Corsini D., Agosti M., Franceschini M. Quality of life and aphasia. Multicentric standardization of a questionnaire. Eura Medicophys. 2006; 42:227-30.
  24. Goodglass H., Kaplan E. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia, 1983.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>